Every 8-K that Evolus, Inc. (EOLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EOLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EOLS filings page.
Evolus, Inc. reported second quarter 2026 net revenue of $84.1 million, up 21% year over year, driven by growth across U.S. and international injectable aesthetics. Gross profit margin was 68.0%, and adjusted gross profit margin was 69.0%.
The company recorded a GAAP operating loss of $4.5 million while delivering positive adjusted EBITDA of $4.7 million, its third consecutive quarter of positive adjusted EBITDA. Cash and cash equivalents were $45.2 million as of June 30, 2026.
Evolus raised its full‑year 2026 net revenue guidance to $330 million to $337 million, increased adjusted gross profit margin guidance to 67.0% to 67.5%, narrowed non‑GAAP operating expense guidance to $212 million to $216 million, and reaffirmed its 2028 outlook for $450 million to $500 million in net revenue and 13% to 15% adjusted EBITDA margins.
Evolus, Inc., through its subsidiary Evolus Pharma B.V., has amended its license, supply and distribution agreement with Symatese Aesthetics to add exclusive rights to commercialize the Estyme® injectable hyaluronic acid gel portfolio in Canada, Australia and New Zealand.
As consideration, Evolus Europe will pay €920,000 in upfront signing payments and up to an additional €1.38 million tied to regulatory approvals, while Symatese remains responsible, at its expense, for development and regulatory activities. The initial term in each new territory is 15 years from first regulatory approval, with automatic five-year renewals. Evolus targets commercialization in 2028, citing a combined neurotoxin and dermal filler market of about $500 million annually across these countries and expects the arrangement, including product transfer pricing and a mid-single digit royalty on net sales, to be accretive to international gross margins.
Evolus, Inc. entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA to develop, commercialize and distribute Profhilo®, an injectable hyaluronic acid product for skin-quality applications, in the United States aesthetics and dermatology markets.
Evolus will fund and manage U.S. development, clinical and regulatory work to seek FDA approval, then purchase product from IBSA under a transfer-price model with periodically adjustable terms. The agreement has no upfront or milestone payments, includes minimum purchase requirements starting in the fourth year after commercial launch, and runs for an initial 15-year term from first FDA approval with optional 5-year renewals. Management describes Profhilo® as a market-leading skin quality injectable abroad that complements Evolus’ existing neurotoxin and dermal filler portfolio and is not expected to change previously communicated 2026 and 2028 financial targets.
Evolus, Inc. reported the results of its Annual Meeting of Stockholders held on June 11, 2026. Stockholders elected Brady Stewart and Vikram Malik as Class II directors, each to serve until the 2029 annual meeting, with Stewart receiving 38,479,626 votes for and Malik 21,310,653 votes for.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 51,230,324 votes for. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 39,350,651 votes for and 336,958 against.
Evolus, Inc. reported first quarter 2026 net revenue of $73.1 million, up 7% from a year earlier, driven by $66.4 million of toxin revenue and $6.7 million from injectable HA gels. Gross margin was 66.9%, and adjusted gross margin 68.0%.
The company posted a GAAP operating loss of $6.8 million and net loss of $10.7 million, but achieved positive Adjusted EBITDA of $0.6 million, its second consecutive quarter of positive adjusted profitability. Cash and cash equivalents were $49.8 million as of March 31, 2026.
Evolus reaffirmed 2026 guidance for net revenue of $327–$337 million, adjusted gross margin of 65.5–67.0%, non‑GAAP operating expenses of $210–$216 million, and a low‑ to mid‑single digit Adjusted EBITDA margin. The company also terminated an unused $50 million at‑the‑market equity sales agreement.
Evolus, Inc. reported a technical change to its board structure. After a prior director departure created an imbalance among its three director classes, the board reclassified director Vikram Malik from Class III to Class II on March 13, 2026 to restore an even distribution.
To accomplish this, Malik briefly resigned as a Class III director and was immediately reappointed as a Class II director, with his board service remaining continuous. He continues as Chairman of the Board and a member of the Compensation Committee, with no new equity awards and existing grants vesting under their original terms.
Evolus, Inc. entered a new senior secured, asset-based revolving credit facility of up to $30.0 million with Eclipse Business Capital, maturing on March 3, 2029, with an uncommitted $10.0 million accordion and a $10.0 million minimum utilization requirement.
Borrowings price at adjusted term SOFR (floor 2.0%) plus a 4.25% margin, with closing fees of 1.0% and prepayment fees starting at 3.0% and stepping down over two years. The facility is secured by substantially all company assets and includes covenants on minimum excess availability and capital expenditures.
For 2025, Evolus generated total net revenue of $297.2 million, up 12%, with Q4 revenue of $90.3 million and Q4 GAAP operating income of $4.2 million. Full-year GAAP loss from operations was $32.7 million and net loss was $51.6 million, while non-GAAP operating loss was $9.4 million. The company ended 2025 with cash of $53.8 million and total liabilities of $249.0 million, resulting in a stockholders’ deficit of $23.1 million.
Evolus projects 2026 revenue of $327–$337 million (growth of 10–13%), adjusted gross margin of 65.5–67.0% and non-GAAP operating expenses of $210–$216 million, aiming for a low- to mid-single digit Adjusted EBITDA margin in 2026 and 13–15% Adjusted EBITDA margins on $450–$500 million revenue by 2028.
Evolus, Inc. filed a current report to disclose that it has issued a press release with preliminary, unaudited net revenue and other operational and financial data for the quarter and year ended December 31, 2025. The press release, dated January 9, 2026, is included as an exhibit to the report.
The company states that this information, including the exhibit, is being furnished rather than filed, which limits the legal exposure associated with these preliminary figures and keeps them separate from formal Securities Act and Exchange Act filings unless specifically incorporated by reference.
Evolus, Inc. (EOLS) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. As provided in General Instruction B.2, the information in Item 2.02 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act, and will only be incorporated by reference if specifically stated in a future filing.
Evolus, Inc. reported a material event on September 8, 2025 via a Current Report on Form 8-K noting two procedural disclosures.
First, the filing references an Employment Agreement described as Exhibit 10.11 to the company's Form S-1 filed January 25, 2018, and states a full copy of that Employment Agreement will be filed as an exhibit to the company's Quarterly Report for the quarter ended September 30, 2025. Second, Evolus furnished a press release as Exhibit 99.1 announcing certain matters described elsewhere in the filing; the exhibit is furnished but not "filed" for Section 18 liability purposes.
The current report contains procedural exhibit references and timing for later exhibit filings but does not include substantive details of the employment terms or the press release text within the body of the filing.